Fucoidans --sulphated polysaccharides extracted from brown algae -could be beneficial in patients with ischemic diseases. Their antithrombotic and proangiogenic properties promote in animals, neovascularization and angiogenesis which prevent necrosis of ischemic tissue. In 1997, endothelial progenitor cells were first identified in human peripheral blood. They are recruited from bone marrow and contribute to neovascularization after ischemic injury. Mobilization of these cells in ischemic sites is an important step in new vessel formation. It is thought that the progenitors interact with endothelial cells, then extravasate and reach ischemic sites, where they proliferate and differentiate into new blood vessels. Although chemokines, cytokines and adhesion molecules are thought to be involved, the precise mechanism of progenitor mobilization is not fully understood. Recent studies suggest that stromal-derived factor 1 plays a critical role at several steps of progenitor mobilization. Given the role of proteoglycans within bone marrow, at the endothelium surface, and in growth factor and chemokine binding, fucoidans might influence the mobilization of endothelial progenitor cells and their incorporation in ischemic tissue. This review provides an update on circulating endothelial progenitors and their role in neovascularization. It focuses on recent advances in our understanding of interactions between these progenitor cells and exogenous sulphated polysaccharides, and their implications for understanding the fucoidan mechanism of action.
INTRODUCTION
This review examines the effect of fucoidans --sulphated polysaccharides extracted from brown seaweeds --on angiogenesis and vasculogenesis.
Angiogenesis is defined as the formation of new blood vessels by sprouting from a pre-existing vascular network [1] [2] [3] . It differs from vasculogenesis, a process in which de novo endothelial cell progenitors emerge from the mesoderm, form vessel rudiments, and organize to form mature vessels [4] [5] [6] [7] . Until recently, vasculogenesis was considered to be restricted to the embryo, while new blood vessel formation in adults was exclusively attributed to angiogenesis. In 1997 Asahara and co-workers detected endothelial progenitor cells (EPC) in human adult peripheral blood [8] . These cells appear to be recruited from bone marrow and incorporated into sites of active revascularization [5, 6, [9] [10] [11] [12] .
They contribute to neovascularization after ischemic injury and are involved in re-endothelialization of vessel implants [13] [14] [15] . Their local transplantation into ischemic tissue quantitatively improves neovascularization, collateral vessel formation, and blood perfusion [5, 11, [16] [17] [18] [19] [20] [21] . Recent experiments show that this transplantation correlates with an increase in capillary densities [16, 17] .
EPCs are present at low frequencies in human adult bone marrow and peripheral blood, and in umbilical cord blood. These immature CD34 + cells can be mobilized from animals bone marrow into the circulation by several compounds including sulphated polysaccharides such as fucoidans [22] .
The anticoagulant activity and potentially severe adverse effects of heparin prompted research into other natural or synthetic sulphated polysaccharides. Fucoidans are of particular interest : at the the same antithrombotic activity as heparin, they have a weaker anticoagulant effect and a lower risk of hemorrhage [23] . They significantly accelerate the interaction between serpin (mainly heparin cofactor II or HCII) and coagulation proteases [24] . They also have various biological properties, such as antiinflammatory [25, 26] and antiviral activity [27] , and can modulate the angiogenic activity of proangiogenic growth factors [28] . Injection of these polyfucoses reduces intimal hyperplasia [29] , promotes revascularization in a rat model of critical hind-limb ischemia [30] , and mobilizes bone marrow stem cells in peripheral blood [22] . 4 How fucoidans promote angiogenesis is not fully clear. However, several studies have shown that the biological properties of these sulphated polyfucoses are a consequence of their charge density and are determined by detailed structural features [31, 32] . Fucoidans seem to act like glycosaminoglycans (GAGs) present on the cell membrane. Recent studies of GAGs provide insights into the possible fucoidan mechanism of action.
Because of their ionic structure, fucoidans have diverse biological properties, ranging from relatively simple mechanical support functions to more intricate effects on cellular processes [32, 33] . Fucoidans bind proteins such as adhesion proteins [34] , growth factors [35] , cytokines [36] , and a variety of enzymes, including coagulation proteases [37] [38] [39] . As a result, they can participate, like GAGs, in cell adhesion, migration, proliferation and differentiation --the key steps of the angiogenic process. They can also modulate clinically relevant phenomena such as angiogenesis, tumor metastasis, and atherosclerosis. In-depth studies of the biochemical mechanisms underlying interactions between GAGs (especially heparan sulphate proteoglycans, or HSPGs, mainly located in the basement membrane and on the mammalian cell surface) and molecules involved in these processes may help us to understand how fucoidans influence angiogenesis and vasculogenesis.
This review provides an update on the effects of fucoidans on angiogenesis and vasculogenesis, the biochemical bases of their interaction with angiogenic growth factors and cell surface molecules, and their mechanisms of action.
I -CONTRIBUTION OF ADULT BONE MARROW-DERIVED CELLS TO BLOOD VESSEL FORMATION
Postnatal neovascularization comprises angiogenesis and vasculogenesis and is regulated by complex interactions of various growth factors, circulating bone marrow-derived precursors, and mature endothelial cells [4-6, 40, 41] .
Angiogenesis is a multistep process leading to the formation of new vessels by "sprouting" from preexisting vessels [1] [2] [3] . It is initiated by angiogenic growth factors such as VEGF. In contrast, vasculogenesis is related to the emergence of blood vessels de novo from vascular endothelial precursor cells known as angioblasts, which differentiate into endothelial cells [6, 42] . During the earliest stages of mammalian development, free angioblasts develop in the mesoderm, assemble into cords and differentiate into an endothelium to form blood vessels [43, 44] . This creates the primary network of vascular endothelial cells that will eventually become major blood vessels. Angiogenesis subsequently remodels this network into small blood vessels by sprouting from the pre-existing vascular network and thereby completing the embryo's circulatory system. These two processes occur simultaneously throughout embryonic development.
Until recently, neovascularization in adults was thought to result exclusively from proliferation, migration, and remodeling of pre-existing endothelial cells, i.e. angiogenesis [1, 43] . The formation of blood vessels from angioblasts was thought to be restricted to the period of embryogenesis. In 1996,
Noishiki et al. raised the possibility that endothelialization of artificial vascular prostheses might be promoted by bone marrow transplantation [15] . Several studies then showed that cells mobilized from bone marrow were incorporated into sites of active neovascularization [8, 45] and participated in the endothelialization of implanted artificial vessel grafts [9, 14] . This prompted researchers to recognize the existence of circulating EPC, and the importance of postnatal vasculogenesis. Autologous infusion of EPC would potentially be a promising therapy for revascularising ischemic tissues.
EPC were isolated from peripheral blood and human umbilical cord blood [6, 8, 17] . These cells and blood cells (erythrocytes, platelets and leukocytes) arise from a common precursor cell, the hemangioblast [46, 47] . Upon appropriate cytokine stimulation, hemangioblasts can give rise to hematopoietic or endothelial cell (EPC) precursors. The two cell types are identified by the presence of common surface antigens such as vascular endothelial cell growth factor receptor (VEGFR-2, also known as Flk-1/KDR), angiopoietin receptor (Tie-2), and CD34 [48] [49] [50] [51] . Persistent expression of VEGFR-2 is associated with differentiation along the endothelial lineage, whereas loss of VEGFR-2 expression characterizes differentiating hematopoietic progeny [7, 8, 13, 17, 51] .
EPC recruitment from bone marrow is very complex [52, 53] . Several studies have shown that regional ischemia is the main factor responsible for local induction of angiogenesis; the extent to which angiogenesis is enhanced is related to the severity of ischemia [40, 45, 54] . [65] , estrogen and fucoidans [22] can also increase the number of mobilized EPC.
After an initial ischemic event, EPC move from the blood into tissues, attracted by proangiogenic factors --chemoattractants produced by the local inflammatory response which activates the endothelium [9] . These chemoattractants are released from HSPGs by endosulfatases [57, 66, 67] .
These latter enzymes break the association between angiogenic growth factor and HSPGs by clipping off key sulphates from heparan sulphate, thereby allowing proangiogenic factors to promote angiogenesis. This step is followed by cell tethering and rolling along the vessel, strong adhesion, and entry into the damaged tissue. A new vascular network develops, then angiogenesis remodels this network into small blood vessels by sprouting.
Throughout this process, the extracellular matrix (ECM) ensures essential functions by supporting key signaling events involved in regulating endothelial cell migration, invasion, proliferation and survival Neighboring endothelial cells then migrate and proliferate, leading to the formation of endothelial cell sprouts and capillary tubes, followed by tight junctions and synthesis of a new basement membrane. [66, 72, 82] . These properties are due in part, to the capacity of these polyanions to bind to the heparin-binding site of growth factors or heparanases via their sulphate groups. Some of them are able to inhibit normal angiogenesis in the chick embryo chorioallantoic membrane [75, 83, 84] . They can also inhibit neovascularization [85, 86] and suppress tumor angiogenesis in experimental models [74, 76, 77, 87, 88] . Their effect on angiogenesis appears to be mediated mainly by their negative charge, molecular weight and degree of sulphation, rather than by a specific carbohydrate structure. Hahnenberger et al. showed that the antiangiogenic properties of heparin were related to the presence of a structure made up of the -[GlcA beta 1,4-GlcNAc alpha 1,4]n-sequence, which is found in non sulphated regions of HSPGs [78] .
II -EFFECTS OF EXOGENOUS SULPHATED POLYSACCHARIDES ON ANGIOGENESIS PROCESS
Interestingly, contrary to other polysaccharides, low-molecular-weight fucoidan fractions potentiate angiogenesis in vitro [28, 89] and in vivo [30] . Fucoidan pretreatment of human umbilical vein endothelial cells (HUVEC) or EPC for 36 to 72 hours enhances FGF-2-dependent angiogenesis [28, 90, 91] , while the addition of high-molecular-weight (HMW) fucoidans directly to the culture medium inhibits growth factor-induced vascular tube formation by endothelial cells [89, 92, 93] .
III -EFFECTS OF FUCOIDAN ON ANGIOGENESIS AND VASCULOGENESIS
Fucoidans are mainly composed of sulphated L-fucose. They are easily extracted from the cell wall of various brown algae [32, 33] , the egg jelly coat of sea urchins [94] , and the body wall of sea cucumber [95] . After reduction into low-molecular-weight fractions by radical depolymerization (ranging from 4000 to 15 000 g/mol), they have been used for in vitro and in vivo coagulation assays. They act as modulators of coagulation [37, [96] [97] [98] [99] [100] [101] and also have antithrombotic activity in vivo in rabbit models of venous thrombosis (jugular venous stasis thrombosis induced by factor Xa injection) and arterial thrombosis [35, [102] [103] [104] . Compared to heparin, at the same level of antithrombotic activity in rabbits, they have lower anticoagulant activity and a lower hemorrhagic risk [104] . Their anticoagulant activities are mediated both by antithrombin and by heparin cofactor II [96, 97] . In the same manner, fucoidans can increase the antithrombin activity of protease nexin-1 (PN-1), a pericellular serpin expressed by vascular cells [39] . They can thus significantly reduce circulating levels of thrombin by catalyzing its inhibition. Fucoidans stimulate endothelial release of tissue factor pathway inhibitor, a potent inhibitor of the coagulation cascade [105] . Finally, fucoidans can promote fibrinolysis by potentiating plasminogen activators [106, 107] and reducing plasminogen activator inhibitor-1 (PAI-1)
release by endothelial cells [108] . All these effects contribute to the antithrombotic action of fucoidans.
Besides their anticoagulant and antithrombotic activities, fucoidans can induce angiogenesis in vitro by modulating the proangiogenic properties of heparin-binding growth factors such as FGF-2. We have previously shown that pre-treatment of HUVEC with low-molecular-weight fucoidan fractions (LMW fucoidan 4000 g/mol, and fucoidan 15 000 g/mol) extracted from the brown algae Ascophyllum nodosum, enhances FGF-2-induced vascular tube formation in a standard in vitro Matrigel model [28, 90] . LMW fucoidan combined with FGF-2 improves endothelial cell proliferation in vitro [109] and cell adhesion to laminin [91] . In the presence of FGF-2, the same fraction induces human EPC to adopt a proangiogenic phenotype [91] is significantly more extensive than that obtained with control cells. This pretreatment provokes marked EPC shape changes, with actin cytoskeleton reorganization and the emergence of protrusions that closely mimic precapillary cords observed during angiogenesis [91] . Over the course of 18h, these cells form hollow tubes on Matrigel.
More recent investigations have established the feasibility of using fucoidan to augment collateral artery development in animal models of hindlimb ischemia. Intravenous administration of a commercial HMW fucoidan extracted from Fucus vesiculosus prolonged the time required for complete occlusion of arterioles and venules by a factor of almost seven [35] . Recently, Luyt et al.
administered the LMW fucoidan fraction and/or FGF-2 to rats with acute hindlimb ischemia at daily intramuscular doses of 5 mg/kg/day and 1 µg/kg/day, respectively [30] . After 14 days of treatment, compared to controls, angiography and necropsy measurement of capillary density showed evidence of increased collateral vessel formation in the lower limb. LMW fucoidan injection improved residual muscle blood flow compared with the control group [30] . This LMW fucoidan is also able to inhibit [113] . Other researchers have shown rapid mobilization of hematopoietic progenitors after IP injection of HMW fucoidan to rats [114, 115] . This mobilization correlates with the release of GAG-bound SDF-1 from its tissue storage sites into the circulation on fucoidan administration [22] . Injection of LMW fucoidan significantly increases the SDF-1 level in rat and mouse peripheral blood but does not modify MMP-9 levels [30, 113] . The injection of heparin and LMW heparin in the same experimental conditions does not induce angiogenesis [30, 73] .
IV -MECHANISM OF ACTION OF FUCOIDAN
What is the mechanism of action of fucoidan ? How does fucoidan differ from other sulphated polysaccharides like heparin? How to explain these properties of fucoidan, when heparin pretreatment of EPC does not potentiate these cells' proangiogenic properties in vitro and has no effect on revascularization of ischemic tissue in vivo?
The biological properties of fucoidan, a sulphated polyfucose, depend on the molecular structure. A wide range of natural and synthetic anionic compounds have been found to interact with proangiogenic growth factors, and especially FGFs [116] [117] [118] [119] . Their interaction with acidic FGF (FGF-1) appears to be primarily related to their charge density [117, 119, 120] . It also depends on the size and location of sulphate groups, the degree of sulphation, and the saccharide chain composition.
The minimal sequence of sulphated polysaccharides necessary to heat-stabilize FGF-1 is four monosaccharide units [119] . The structural requirements for fucoidan interaction with coagulation factors and target proteases are also stereospecific [31, 32] .
The type of fucoidan, its sulphation and molecular weight, and the conformation of its sugar residues Various data indicate that sulphation is critical for fucoidan activity in vivo. In particular, desulphated fucoidan fails to promote angiogenesis in vitro [91] [126] and also trigger an increase in blood SDF-1 levels and immature cell mobilization [22] . Like fucoidan, these chondroitin sulphate species that bear sulphated fucose chains express antithrombotic activity in experimental animals with venous and arterial thrombosis [127] . Branched sulphated fucoses are the key motif responsible for this activity, as shown by comparing native and chemically modified defucosylated and/or desulphated chondroitins [126] . The number of sulphate groups, and changes to the molecular backbone, significantly influence the biological properties of these compounds.
Fucoidan can disrupt heparan sulphate-growth factor/cytokine complexes, and can substitute for cellsurface heparan sulphates in stabilizing the growth factor/growth factor receptor interaction.
Fucoidan binds growth factors and is capable of modulating the biological activity of angiogenic heparin-binding growth factors
Owing to its ionic structure, fucoidan, like heparin, can bind and modulate the activity of a large number of proteins [33, 128] facilitates GF-GF receptor interaction. As a result, it may increase the radius of growth factor diffusion.
Fucoidan interacts with cell membranes
The proangiogenic activity of fucoidan is also related to direct interaction of the polysaccharide with cell membranes Fig. (4) . Experiments underway in our laboratory indicate that FITC-fucoidan binds to the EPC outer membrane and is internalized by endocytosis within 30 minutes. Because fucoidan binds to cell membranes, it could increase local growth factor concentrations in the close vicinity of the relevant receptor. Endothelial cell surface-bound fucoidan could also act as a co-receptor for angiogenic growth factors.
Fucoidan may mediate growth factor-induced EPC differentiation by interacting with a "receptor" that promotes endothelial cell adhesion, migration, proliferation and differentiation, and that co-operates with a growth factor receptor, transducing the intracellular signals required to induce the angiogenic phenotype. This putative fucoidan receptor might contain a carbohydrate-binding domain that interacts with the fucoidan carbohydrate backbone. Candidates include E-selectin and CD44 --cell adhesion molecules that are present on the endothelial cell membrane and are expressed by EPC. Specific carbohydrate modifications such as fucosylation and sulphation are critical for selectin binding [135] .
Because of the spatial pattern of the sulphated saccharide structure, fucoidan can mimic the clustering of sulphated, sialylated and fucosylated oligosaccharides on the cell surface and can provide the appropriate structural backbone to bind selectins. This is in keeping with previous studies showing the high affinity of selectins for HMW fucoidan [136, 137] . Nevertheless, according to Frenette et al, HMW fucoidan also acts in a selectin-independent fashion, as it is effective in selectin-deficient mice [115] . HMW fucoidan can bind to non hematopoietic cells lacking selectins [138] .
A recent study showed that this HMW fucoidan was also able to bind to non selectin receptors such as integrin α M β2 on myeloid cells [139] . Integrins can transduce extracellular signals [140] . The possible collaboration of α M β2 or other integrins with fucoidan remains to be addressed.
We have shown that tube formation correlates with overexpression of the α6 integrin subunit on the endothelial cell surface [28, 90, 91] . RT-PCR revealed that larger amounts of α6 mRNA were produced after LMW fucoidan stimulation. This α6 overexpression results from transcriptional upregulation [90] . The fucoidan-mediated increase in α6 integrin subunit expression is associated with increased cell adhesion to laminin [91] . The impact of fucoidan on α6 subunit expression is less marked in EPC and is related to baseline α6 subunit integrin expression (stronger on EPC than on HUVEC) [91] . The integrin α6 chain, when assembled with integrin β1 or β4 subunits, forms major receptors for laminin. In human bone marrow, laminin isoforms are present at sites of hematopoietic cell trafficking [141] and promote progenitor adhesion and migration through interaction with integrin Throughout our experiments, we never detected variations in the expression of the laminin receptor β1
subunit. This is consistent with the study of Sastry et al suggesting that the α6 subunit regulates differentiation, whereas the β1 subunit triggers proliferation : a α6/β1 ratio below one triggers proliferation, while a ratio above one triggers differentiation [147] . At the concentrations inducing α6 overexpression, fucoidan has no effect on the expression of other endothelial markers (KDR, Flt-1, Tie-2, PECAM, CD144).
Fucoidan enhances EPC mobilization through SDF-1 release
In vivo, fucoidan is exposed to a complex environment containing numerous proteins in solution and bound to cell surfaces. It can thus bind to and inactivate cationic proteins, and act on other proteins, possibly triggering a cellular response on top of its anticoagulant activity. Part of the fucoidan can interact with proteases involved in coagulation (e.g. thrombin) and with protease inhibitors such as antithrombin and HCII [24, 37, 38] . It can thus reduce circulating levels of thrombin by catalyzing its inhibition. On the other hand, fucoidan can bind to adherent proteins such as fibronectin, collagen and laminin, which are all expressed in bone marrow [34] . Perfusion with HMW fucoidan was shown to reduce neutrophil [148] and eosinophil [149] 1 -Several lines of evidence suggest that fucoidan acts through SDF-1. Injection of LMW fucoidan to rats and mice significantly increases the SDF-1 level in peripheral blood [30] . High levels of SDF-1 mobilize EPC in the peripheral circulation and enhance their recruitment to the vasculature [55, [57] [58] [59] . The cytokine is anchored to the membrane of stromal cells, endothelial cells or the ECM by binding to HSPG [152] . Fucoidan could thus specifically displace sequestered SDF-1 from its HSPG anchors and thus contribute to its release into the circulation. According to Sweeney et al. [22, 114] , who are working on hemoatopoietic progenitors, the amount of SDF-1 released into the circulation is sufficient to trigger the observed cell mobilization. In addition to SDF-1, levels of other chemokines 2 -Fucoidan ligation to the endothelium might trigger signaling events that could result in EPC egress into the circulation. However, during transmigration through the endothelium, the progenitors traverse the endothelial cell monolayer and the underlying subendothelial basement membrane. Consequently, transmigrating cells interact with endothelial cells, GAG and EMC adhesion proteins. The laminin receptor integrin α6, involved in the homing of stem cells to bone marrow [143] , is expressed by EPC [91] . Its expression might be required for EPC migration, and its overexpression after fucoidan pretreatment might facilitate EPC homing towards ischemic sites. 
